Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Therapeutic targeting of lipidated amino acid deficiency ameliorates MASH via a PPARα/CCL2 axis

ABSTRACT: Metabolic dysfunction-associated steatohepatitis (MASH), affects nearly one-third of the global population with limited pharmacotherapy approved, underscoring the urgent need for new therapeutic strategies. N-acyl amino acids (NAAs), comprising amino acids linked to long-chain fatty acid acyl groups, are gaining interest, yet their metabolic regulation in MASH remains elusive. Metabolomic profiling in mice and humans with MASH revealed a marked depletion of NAAs, particularly C18:1-Leu, which inversely correlated with disease severity. The bidirectional PM20D1 expression was suppressed in the livers of human and mice with MASH, as well as in lipid-loaded primary mouse hepatocytes and hepatic cell lines. Stable isotope tracing studies in mice with and without MASH confirmed reduced biosynthesis of C18:1-Leu. Genetically, hepatocyte-specific overexpression of PM20D1 or pharmacological treatment with exogenous C18:1-Leu significantly attenuated or reversed established MASH. Mechanistically, C18:1-Leu bound and activated peroxisome proliferator-activated receptor alpha (PPARα), enhancing fatty acid β-oxidation and suppressing the NF-κB/CCL2 axis, thereby reducing hepatic macrophage infiltration, inflammation, and fibrosis. These therapeutic effects were abolished in hepatocyte-specific PPARα- and CCL2-deficient mice, identifying C18:1-Leu as a promising metabolic therapy for MASH.

ORGANISM(S): Mus musculus

PROVIDER: GSE304787 | GEO | 2026/07/01

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

PM20D1-derived treatment induces microglia association with amyloid plaques and improves Alzheimer’s disease pathologies

Project description:Alzheimer’s disease (AD) is a growing epidemic threat for which no effective treatment is available. Recently, Peptidase M20 Domain Containing 1 (PM20D1) has emerged as a novel neuroprotective factor epi-genetically altered in AD. PM20D1 low expression carriers show increased AD risk, and PM20D1-overexpressing mice reduced amyloid levels and cognitive deficits, through a still unknown mechanism. PM20D1 overexpression, in turn, has shown to facilitate the synthesis of N-acyl amino acids (NAAAs), particularly of N-oleoyl-L-Leucine (C18:1-Leu), the potential role of which in AD also remains unknown. Here, we report that C18:1-Leu treatment is sufficient to improve AD pathologies and phenotypes in two independent models of AD. We show that it alleviates motility deficits and amyloid aggregation in the GMC101 strain of C.elegans. We demonstrate that C18:1-Leu treatment also reduces cognitive deficits and amyloid burden in APP/PS1 mice. Furthermore, we provide evidence for a C18:1-Leu-induced microglia association with amyloid plaques, thereby reducing their size, number and toxicity, and for an enhanced neuroprotection, thereby reducing neuronal damage. Finally, we show that C18:1-Leu treatment also increases Aβ chemotaxis and clearance in microglia cultures, and increases cell viability in neuronal cells. In sum, our results support the use of C18:1-Leu as a potential therapeutic agent for the treatment of AD.

2026-05-12 | GSE214352 | GEO

Genetic and pharmacological targeting of hepatic oxalate overproduction ameliorates metabolic dysfunction-associated steatohepatitis

Project description:Metabolic dysfunction-associated steatohepatitis (MASH) is on the rise, and with limited pharmacological therapy available, identification of new metabolic targets is urgently needed. Oxalate is a terminal metabolite produced from glyoxylate by lactate dehydrogenase (LDHA). The liver-specific alanine-glyoxylate aminotransferase (AGXT) detoxifies glyoxylate, preventing oxalate accumulation. We report that AGXT is suppressed and LDHA is activated in livers from patients and mice with MASH, leading to oxalate overproduction. In turn, oxalate promotes steatosis in hepatocytes by inhibiting peroxisome proliferator activated receptor-alpha (PPARα) transcription and fatty acid β-oxidation (FAO), and induces monocyte chemotaxis via C-C motif chemokine ligand 2. In male mice with diet-induced MASH, blocking oxalate overproduction through hepatocyte-specific AGXT overexpression or pharmacological inhibition of LDHA potently lower steatosis, inflammation, and fibrosis by inducing PPARα-driven FAO, and suppressing monocyte chemotaxis, nuclear factor-kappaB and transforming growth factor-beta targets. These findings highlight hepatic oxalate overproduction as a new target for the treatment of MASH.

2024-08-07 | GSE265985 | GEO

Hepatocyte Circadian Clocks Control Cholesterol Metabolism and Protect From Metabolic Dysfunction-Associated Steatohepatitis (MASH) [RNAseq_diurnal]

Project description:The circadian clock synchronizes physiological processes with the 24-hour light-dark cycle. Clock disruption contributes to metabolic disorders, including metabolic dysfunction-associated steatohepatitis (MASH). Here, we investigated the role of the hepatocyte clock in MASH using hepatocyte-specific Bmal1 deletion (Hep-Bmal1KO) mice. Hep-Bmal1KO mice showed faster MASH progression with increased hepatic cholesterol, inflammation, and fibrosis. Transcriptomic and lipidomic analyses revealed dysregulated cholesterol metabolism in Hep-Bmal1KO mice, marked by reduced expression and disrupted rhythmicity of key cholesterol-related genes. Bioinformatic analyses identified Chrebp as a potential co-regulator of these transcriptional changes. In an in vitro model with palmitate exposure and gene silencing, we found that Bmal1, but not Chrebp, regulated cholesterol accumulation, indicating Bmal1’s specific role in hepatic cholesterol metabolism. Translating our findings to a human patient cohort revealed a significantly shifted circadian phase, despite no marked effect on hepatic cholesterol levels in the livers of patients with more advanced liver disease (i.e., MASH) compared to simple steatosis. Taken altogether, our findings offer a roadmap to understand the hepatocyte clock's role in MASH and its potential as a therapeutic target.

2026-05-28 | GSE304691 | GEO

Hepatocyte Circadian Clocks Control Cholesterol Metabolism and Protect From Metabolic Dysfunction-Associated Steatohepatitis (MASH) [RNAseq_palmitate_silencing]

2026-05-28 | GSE304692 | GEO

Quantitative proteomics analysis of liver from LONP1 Knockout mice

Project description:The mechanisms of hepatic stellate cell (HSC) activation and the development of liver fibrosis remains largely unknow. Here, we revealed a fibrosis related mechanism of hepatocytes-HSCs crosstalk regulated by hepatocyte LONP1. We demonstrate that hepatocyte LONP1 expression is decreased in HFD-fed mice and MASH patients. Liver-specific LONP1 deficiency increases orotic acid level and aggravates MASH-induced liver fibrosis in mice. We have identified DHODH as a substrate that is selectively degraded by LONP1 in an ATP-dependent manner. Moreover, activation of LONP1 reduces orotic acid levels and alleviates MASH-induced fibrosis in mice. Mechanistically, LONP1 mediates DHODH turnover, maintaining lower orotic acid levels to inhibit ATF3-mediated HSC proliferation and activation, thereby preventing liver fibrosis. Furthermore, plasma orotic acid levels are negatively correlated with liver LONP1 levels in humans. Therefore, targeting LONP1-mediated hepatocyte-HSC communication may represent a promising therapeutic strategy for MASH-induced liver fibrosis.

2025-09-23 | PXD055467 | Pride

Single-nucleus RNA-seq profiling of mouse livers with hepatocyte-specific ablation of Themis under MASH diet feeding

Project description:Metabolic dysfunction-associated steatohepatitis (MASH) is a severe chronic liver condition characterized by hepatocyte steatosis, inflammation and fibrosis, with a rising prevalence globally, posing significant health risks and potentially leading to complications such as cirrhosis, liver failure, and increased mortality. Previous study in our lab has identified Themis as a highly up-regulated gene in hepatocytes during MASH progression using a diet-induced mouse model. To gain further insights into the roles of Themis in regulating hepatic responses to MASH diet, we generated mice with hepatocyte-specific ablation of Themis (HKO). The HKO mice exhibited worse MASH symptoms, including more severe steatosis, liver injury, fibrosis and more immune cell infiltration, relative to their Themis flox/flox control littermates.

2026-02-10 | GSE300162 | GEO

Inhibition of Peripheral Serotonin Activates Hepatic AMPK and Reduces Monocyte-Derived Liver Macrophages, Ameliorating Obesity-Associated Fibrosis

Project description:Monocyte-derived liver macrophages are critical in the pathogenesis of metabolic dysfunction-associated steatohepatitis (MASH) and liver fibrosis, but their recruitment mechanisms remain unclear. Serotonin (5-hydroxytryptamine, 5HT) is a conserved monoamine synthesized by tryptophan hydroxylase (Tph) 1 in peripheral tissues and Tph2 in the brain. We show that in mice housed at thermoneutrality and fed a high-fat, high-fructose diet, inhibition of peripheral serotonin (pe5HT) through genetic deletion of Tph1 prevents MASH independently of reductions in body weight. Liver flow cytometry and single-nuclei sequencing showed reduced pro-inflammatory Ly6Chigh monocytes, monocyte-derived Kupffer cells (moKCs), and lipid-associated macrophages (LAMs) in Tph1 KO mice. Tph1 deletion also decreased circulating monocytes, specifically Ly6Chigh monocytes. A single 5HT injection increased Ly6Chigh monocytes, while Tph1 KO mice had reduced monocytes without affecting bone marrow monocytes. Mechanistically, serotonin inhibition increases liver AMPK activity, and this is important for reducing CCL2 and monocyte recruitment. These findings link two ancient energy sensors, 5HT and AMPK, with obesity-associated liver fibrosis.

2025-10-30 | E-MTAB-15760 | biostudies-arrayexpress

CXCL6 exacerbates metabolic dysfunction-associated steatohepatitis by suppressing LPIN1-mediated fatty acid oxidation in hepatocytes

Project description:Progression of hepatic steatosis to metabolic dysfunction-associated steatohepatitis (MASH) involves impaired fatty acid (FA) oxidation, which causes lipotoxicity and inflammation in hepatocytes. MASH is characterized by upregulation of the neutrophil-recruiting chemokine CXCL6. Although hepatocytes produce CXCL6, its direct contribution to MASH progression in hepatocytes, beyond neutrophil recruitment, remains unclear. Here, we show that Cxcl5, the murine homolog of human CXCL6, promotes steatosis-to-MASH transition when overexpressed in the mouse liver, whereas Cxcl5 deficiency protects against diet-induced MASH. Transcriptomic analysis of Cxcl5-deficient mice showed upregulation of FA metabolism genes. This is accompanied by reduced hepatic FA levels and increased Lipin-1 (LPIN1) expression, which activates PPARα. In vitro, recombinant mouse CXCL5 suppressed LPIN1 and PPARα expression in mouse hepatocytes, whereas Cxcl5-deficient hepatocytes exhibited elevated levels of both. Mechanistically, CXCL6 induced JNK activation, leading to inhibitory phosphorylation of the glucocorticoid receptor (GR). Luciferase assays demonstrated that CXCL6 attenuated GR-dependent LPIN1 promoter activation. Lpin1 knockdown reversed the protective phenotype in Cxcl5-deficient mice, indicating that LPIN1 suppression is essential for CXCL6-driven MASH progression. Human MASH samples consistently exhibited reduced hepatic LPIN1 expression and an inverse correlation between LPIN1 and CXCL6 expression. In conclusion, CXCL6 drives MASH progression by inhibiting GR-mediated LPIN1 transactivation in hepatocytes, impairing FA oxidation and promoting lipotoxicity.

2026-06-03 | GSE325102 | GEO

Coagulation protease-activated receptor-2 (PAR2) promotes dyslipidemia, obesity and MASLD through suppression of a hepatic pioneer factor HNF4a

Project description:MASLD and its more severe version, MASH, are attributable to metabolic dysfunction and are associated with cardiometabolic disease, atherothrombosis, and obesity. The exact pathophysiological mechanisms linking MASLD and CVD have yet to be elucidated but share common metabolic abnormalities that could interact synergistically to increase the risk of both heart disease and liver disease. Protease-activated receptor 2 (PAR2), a receptor activated by prothrombotic coagulation proteases that are dysregulated in inflammatory and fibrotic diseases, is emerging as a new drug target for MASH. Using patient samples, we discovered that expression of liver PAR2 is increased in the livers of obese patients with MASLD and MASH.To address the direct contribution of hepatocyte PAR2 to progression of MASLD and obesity, we fed hepatocyte-specific PAR2 knockout mice(PAR2dHep), whole-body PAR2-deficient mice(PAR2 KO), and control floxed WT mice(PAR2fl/fl) high-fat diet and conducted metabolic, biochemical and RNA-seq analyses. Hepatocyte-specific deletion of PAR2 caused a reduction in body weight and significantly lowered triglycerides and cholesterol levels in plasma and livers of mice fed high-fat diet. Analysis of bulk liver RNA seq data showed that global or hepatocyte-specific deletion of PAR2 resulted in significant improvements in fatty acid metabolic and reverse cholesterol transport pathways in liver.These data provide support that targeting hepatic PAR2 may potentially provide broad liver and cardiometabolic benefits to patients with MASLD and MASH.

2026-05-20 | GSE319296 | GEO

The enedioic acid analogue 326E alleviates MASH in preclinical studies and its signatures in patients via dual targeting at ACLY and PPARα [RNA-Seq]

Project description:The alarming rise in the prevalence of metabolic dysfunction-associated steatohepatitis (MASH) is attributed significantly to dysregulated lipid metabolism. The present study discovered that a novel enedioic acid ACLY inhibitor 326E, an investigational new drug in Phase 2a study for hypercholesterolemia, markedly reduces hepatic lipid accumulation and alleviates MASH in two different mouse models of MASH. Mechanistic studies demonstrated that 326E exerts these effects not only by inhibiting ATP-citrate lyase (ACLY) to reduce de novo lipogenesis but also as a PPARα agonist to increase hepatic fatty acid oxidation with promoted mitochondrial biogenesis. Subsequent studies in cynomolgus monkeys (Macaca fascicularis) confirmed the effectiveness of 326E for MASH in primate species. In a randomized Phase 1b/2a clinical trial in MASH patients 326E was well tolerated and demonstrated a therapeutic potential for MASH signatures. Our results reveal a promising therapeutic potential of 326E for MASH via distinctive dual mechanisms of inhibiting ACLY while activating PPARα.

2025-10-17 | GSE279675 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data